Gilead Sciences, Inc. today announced two appointments to the company’s senior leadership team. Kevin Young CBE has been appointed Chief Operating Officer, and Martin Silverstein, MD has been appointed Executive Vice President, Strategy.
Both Mr. Young and Dr. Silverstein will report to John F. Milligan, PhD, President and Chief Executive Officer. The company also announced that Paul R. Carter, Executive Vice President, Commercial Operations, has decided to depart Gilead and pursue other opportunities.
As Chief Operating Officer, Mr. Young will assume responsibility for Gilead’s worldwide commercial organization, and facilities and operations. From 2004 through 2014, Mr. Young served as Gilead’s Executive Vice President of Commercial Operations. Since 2014, he has held the role of senior advisor to the company. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his “services to the healthcare and pharmaceutical industries.”
“I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years,” said Dr. Milligan. “Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.”
Dr. Silverstein will oversee Gilead’s corporate development, commercial planning and alliance management functions. He previously held the role of Executive Vice President and Chief Strategy Officer at Anthem from April 2014 through December 2015. Prior to Anthem, Dr. Silverstein spent 28 years in roles of increasing responsibility at The Boston Consulting Group, including serving as Global Leader of its Health Care Practice, Senior Partner and Managing Director. He received a medical degree from Yale University, an MBA from Harvard Business School and a bachelor’s degree from the University of Pennsylvania. He completed his internal medicine residency at Boston’s Beth Israel Hospital and is board certified in Internal Medicine.
“I’m very pleased to welcome Marty to the Gilead team,” commented Dr. Milligan. “His vast expertise in the healthcare sector, across biopharmaceuticals, pharmacy benefit management, health insurance and healthcare delivery, will be of great value to Gilead as we see the complexity of our business increase around the world. I’m looking forward to working with Marty and the rest of the company’s senior leadership team to deliver continued growth and bring more medicines to more people around the world.”
Source: Gilead Sciences
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
